ISRCTN08931855 https://doi.org/10.1186/ISRCTN08931855

Rotation of antihypertensive drugs in ethnic groups

Submission date 19/12/2005	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [_] Record updated in last year
Registration date 19/12/2005	**Overall study status** Completed	
Last Edited 03/11/2008	**Condition category** Circulatory System	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr R.P. Koopmans

Contact details
Academic Medical Centre
Department of Pharmacology and Therapy
P.O. Box 22660
Amsterdam
Netherlands
1100 DD
r.p.koopmans@amc.uva.nl

Additional identifiers

Protocol serial number
NTR384

Study information

Scientific Title

Acronym

ROTATIE

Study objectives
Inter-individual variation in antihypertensive drug response can be predicted through lifestyle, demographics and plasma drug levels.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Received from the local medical ethics committee

Primary study design
Interventional

Study design
Randomised, active controlled, crossover group trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Hypertension

Interventions
Randomised, crossover trial. Six-week periods of antihypertensive drug treatment in monotherapy with three weeks washout. Drugs:
1. Lisinopril
2. Nebivolol
3. Barnidipine
4. HCl thiazide
5. Eprosartan

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Lisinopril, nebivolol, barnidipine, HCl thiazide, eprosartan

Primary outcome(s)
1. Office blood pressure measured with an automatic device
2. Side effects measured with a questionnaire

Key secondary outcome(s)
No secondary outcome measures

Completion date

31/12/2004

Eligibility

Key inclusion criteria
Subjects with uncomplicated hypertension between the ages of 36 and 60 years.

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Key exclusion criteria
1. Serious hypertensive organ damage
2. Co-morbidity

Date of first enrolment
01/01/2001

Date of final enrolment
31/12/2004

Locations

Countries of recruitment
Netherlands

Study participating centre
Academic Medical Centre
Amsterdam
Netherlands
1100 DD

Sponsor information

Organisation
Academic Medical Centre (AMC) (Netherlands)

ROR
https://ror.org/03t4gr691

Funder(s)

Funder type
Industry

Funder Name
Yamanouchi Europe BV (The Netherlands)

Funder Name
Solvay SA (Belgium)

Funder Name
Menarini Benelux NV (Belgium)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration